Archive · 2 Jan 2026
Obesity Drugs May Boost Indian Pharma Deals
Some medicines that help people with weight issues will soon be available for other companies to make because their special protection, called a patent, is ending in March 2026 in India.
A smart person who studies medicines, named Shrikant Akolkar, thinks this will lead to more deals where Indian medicine companies can sell these drugs.
This is because there are many people in India and other places who might need these medicines, and companies that know how to sell them locally will be preferred.
So, we might see more agreements happening as we get closer to that date.
Patent for obesity drugs expires in March 2026 in India.
Indian drugmakers may secure licensing and distribution deals.
Local distribution and marketing presence are key factors.
Large population in India and other markets drives demand.
Analysts expect more deals as the patent expiry approaches.
- Who
- Indian drugmakers and pharmaceutical analysts
- What
- Potential licensing and distribution deals for obesity drugs
- When
- As the patent expires in March 2026
- Where
- India and other markets with large populations
- Why
- To leverage local distribution and marketing presence
- Patent Expiry
- March 2026 (India)
- Market Potential
- Large population in India and other markets
- Analyst
- Shrikant Akolkar, Nuvama
- Expected Outcome
- Potential licensing and distribution deals for Indian drugmakers
- Key Factor
- Local distribution and marketing presence